Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Resource use · a) pharmaceutical companies, b) community health centre staff, c) health service users Interventions to reduce corruption in the health sector (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare and health outcomes · a) pharmaceutical companies, b) community health centre staff, c) health service users Interventions to reduce corruption in the health sector (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Resource use · doctors Interventions to reduce corruption in the health sector (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare and health outcomes · doctors Interventions to reduce corruption in the health sector (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse effects · health professionals Interventions to reduce corruption in the health sector (2016) · Cochrane | no estimate extracted | NR | No studies |
Intracystic bleomycin vs other types of intracystic treatment Survival · cystic craniopharyngiomas in children from birth to 18 years old Intracystic bleomycin for cystic craniopharyngiomas in children (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events 1 mg morphine vs 2 mg morphinePercentage of participants with any adverse event · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events 1 mg morphine vs 4 mg/5 mg morphinePercentage of participants with any adverse event · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | NR | No studies |
IA morphine vs IM morphine Analgesia durationtime duration from the end of surgery to the time of first analgesic consumption. Scale from: 0 to 100. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | NR | No studies |
IA morphine vs IM morphine Adverse eventsPercentage of participants with any adverse event · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | NR | No studies |
External inspection of compliance with COHSASA hospital accreditation standards vs no external inspection Mortality and condition‐specific measures of outcome related to patients' health External inspection of compliance with standards for improved healthcare outcomes (2016) · Cochrane | no estimate extracted | NR | No studies |
External inspection of compliance with COHSASA hospital accreditation standards vs no external inspection Unanticipated/adverse consequences External inspection of compliance with standards for improved healthcare outcomes (2016) · Cochrane | no estimate extracted | NR | No studies |
External inspection of compliance with COHSASA hospital accreditation standards vs no external inspection Costs and cost effectiveness External inspection of compliance with standards for improved healthcare outcomes (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Unanticipated/adverse consequences External inspection of compliance with standards for improved healthcare outcomes (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Costs and cost effectiveness External inspection of compliance with standards for improved healthcare outcomes (2016) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 PUFA supplements vs placebo Memory ‐ not measured · people with mild to moderate Alzheimer's disease Omega‐3 fatty acids for the treatment of dementia (2016) · Cochrane | no estimate extracted | NR | No studies |
CHM vs HT Outcomesa · Women with menopausal symptoms Chinese herbal medicine for menopausal symptoms (2016) · Cochrane | no estimate extracted | NR | No studies |
GM‐CSF vs placebo Time to progression to AML · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |
GM‐CSF vs placebo Quality of life · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |
G‐CSF vs placebo Quality of life · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |
G‐CSF vs placebo Severe adverse events · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |
Fingolimod 0.5 mg vs placebo Outcomes at 24 months · people with relapsing‐remitting multiple sclerosis Fingolimod for relapsing‐remitting multiple sclerosis (2016) · Cochrane | no estimate extracted | NR | No studies |
Fingolimod 0.5 mg vs interferon beta‐1a Outcomes at 12 months · people with relapsing‐remitting multiple sclerosis Fingolimod for relapsing‐remitting multiple sclerosis (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Standardised tests of reading, writing, spelling or mathematics skills (overall) · children with specific learning disorders Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality · patients with venous leg ulcers Oral aspirin for treating venous leg ulcers (2016) · Cochrane | no estimate extracted | NR | No studies |
Manual acupressure vs routine care Pain1 Not measured · patients with end‐stage kidney disease Acupuncture and related interventions for symptoms of chronic kidney disease (2016) · Cochrane | no estimate extracted | NR | No studies |
Intravenous midazolam vs placebo Incomplete procedures · adults requiring sedation before gastrointestinal endoscopy and bronchoscopy Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Intravenous midazolam vs placebo Anterograde amnesia (defined by number of participants who recalled the procedure) · adults requiring sedation before gastrointestinal endoscopy and bronchoscopy Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Intravenous midazolam vs placebo Disinhibition or excitation · adults requiring sedation before gastrointestinal endoscopy and bronchoscopy Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Intravenous midazolam vs placebo Allergic or anaphylactoid reaction · adults requiring sedation before gastrointestinal endoscopy and bronchoscopy Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Oral midazolam vs chloral hydrate Anterograde amnesia (defined by number of participants who recalled the procedure) · children requiring sedation before procedures that require motion control, including echocardiography, lumbar… Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Oral midazolam vs chloral hydrate Disinhibition or excitation · children requiring sedation before procedures that require motion control, including echocardiography, lumbar… Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Oral midazolam vs chloral hydrate Discomfort · children requiring sedation before procedures that require motion control, including echocardiography, lumbar… Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Oral midazolam vs chloral hydrate Allergic or anaphylactoid reaction · children requiring sedation before procedures that require motion control, including echocardiography, lumbar… Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Oral midazolam vs placebo Anterograde amnesia (defined by number of participants who recalled the procedure) · children requiring sedation before micturating cystourethrograms and Kirschner wire removal and adults undergoing… Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Oral midazolam vs placebo Disinhibition or excitation · children requiring sedation before micturating cystourethrograms and Kirschner wire removal and adults undergoing… Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Oral midazolam vs placebo Allergic or anaphylactoid reaction · children requiring sedation before micturating cystourethrograms and Kirschner wire removal and adults undergoing… Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Intranasal midazolam vs placebo Anterograde amnesia (defined by number of participants who recalled the procedure) · Children requiring sedation before voiding cystourethrograms and adults undergoing MRI Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Intranasal midazolam vs placebo Disinhibition or excitation · Children requiring sedation before voiding cystourethrograms and adults undergoing MRI Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Intranasal midazolam vs placebo Discomfort/pain · Children requiring sedation before voiding cystourethrograms and adults undergoing MRI Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Intranasal midazolam vs placebo Allergic or anaphylactoid reaction · Children requiring sedation before voiding cystourethrograms and adults undergoing MRI Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Intravenous midazolam vs diazepam Disinhibition or excitation · adults and children requiring sedation before gastrointestinal endoscopy and bronchoscopy Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Intravenous midazolam vs diazepam Allergic or anaphylactoid reaction · adults and children requiring sedation before gastrointestinal endoscopy and bronchoscopy Midazolam for sedation before procedures (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Improvement in nutritional intake · participants with schizophrenia Dietary advice for people with schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Change in measures of nutritional status: weight (kg), body mass index (kg/ m2), and waist/ hip ratio (cms) · participants with schizophrenia Dietary advice for people with schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mental state · participants with schizophrenia Dietary advice for people with schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinically important adverse effects · participants with schizophrenia Dietary advice for people with schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Measures of physiological function · participants with schizophrenia Dietary advice for people with schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for all doses of nasal decongestant vs placebo Secondary outcome: All adverse events · adult patients with the common cold Nasal decongestants in monotherapy for the common cold (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall survival · people diagnosed with chemotherapy‐induced anemia The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… (2016) · Cochrane | no estimate extracted | NR | No studies |